- Conditions
- Biliary Carcinoma, Gall Bladder Carcinoma, Cholangiocarcinoma, Gastrointestinal Tumor
- Interventions
- Cisplatin, Gemcitabine, Copanlisib
- Drug
- Lead sponsor
- H. Lee Moffitt Cancer Center and Research Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2021
- U.S. locations
- 1
- States / cities
- Tampa, Florida
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 97–120
of 12,647
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Non-Small-Cell Lung Carcinoma
- Interventions
- TG4010, placebo
- Biological · Drug
- Lead sponsor
- Transgene
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 222 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2016
- U.S. locations
- 12
- States / cities
- Scottsdale, Arizona • Topeka, Kansas • Louisville, Kentucky + 9 more
- Conditions
- Head and Neck Squamous Cell Carcinoma (HNSCC), Squamous Cell Carcinoma of the Head and Neck
- Interventions
- Ficerafusp alfa, Pembrolizumab
- Drug
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts
- Conditions
- Breast Cancer, Cancer Survivor, Fatigue, Pain
- Interventions
- exercise intervention, educational intervention, complementary or alternative medicine procedure, fatigue assessment and management, management of therapy complications, pain therapy, quality-of-life assessment
- Behavioral · Other · Procedure
- Lead sponsor
- Clayton State University
- Other
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 54 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2006
- U.S. locations
- 2
- States / cities
- Atlanta, Georgia • Morrow, Georgia
- Conditions
- Brain and Central Nervous System Tumors
- Interventions
- imatinib mesylate, temozolomide, pharmacological study
- Drug · Other
- Lead sponsor
- Duke University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 65 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2008
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Advanced Cancer, Squamous Cell Carcinoma, Carcinoma, Squamous Cell of Head and Neck, Lung Squamous Cell Carcinoma Stage IV, Anal Squamous Cell Carcinoma, Carcinoma, Non-Small-Cell Lung
- Interventions
- Prexasertib
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2016
- U.S. locations
- 5
- States / cities
- Sarasota, Florida • Oklahoma City, Oklahoma • Nashville, Tennessee + 1 more
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- Carboplatin, Paclitaxel, Bevacizumab
- Drug
- Lead sponsor
- SCRI Development Innovations, LLC
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2013
- U.S. locations
- 6
- States / cities
- Fort Lauderdale, Florida • Terre Haute, Indiana • Louisville, Kentucky + 3 more
- Conditions
- Metastatic Prostate Neuroendocrine Carcinoma, Metastatic Prostate Cancer
- Interventions
- Nivolumab, Ipilimumab, Carboplatin, Cabazitaxel
- Drug
- Lead sponsor
- Andrew J. Armstrong, MD
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 41 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2028
- U.S. locations
- 3
- States / cities
- New York, New York • Durham, North Carolina • Houston, Texas
- Conditions
- Head and Neck Cancer
- Interventions
- cisplatin, ixabepilone
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2002
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Platinum-refractory Ovarian Carcinoma, Platinum-resistant Ovarian Cancer, Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Primary Peritoneal Carcinoma, Platinum-Refractory Fallopian Tube Carcinoma, Platinum-Refractory Primary Peritoneal Carcinoma, Platinum-Sensitive Ovarian Cancer in Which the Participant Has Allergy or Severe Intolerance to Carboplatin and/or Cisplatin, Platinum-Sensitive Fallopian Tube Carcinoma in Which the Participant Has Allergy or Severe Intolerance to Carboplatin and/or Cisplatin, Platinum-Sensitive Primary Peritoneal Carcinoma in Which the Participant Has Allergy or Severe Intolerance to Carboplatin and/or Cisplatin
- Interventions
- TILT-123, pembrolizumab, pegylated liposomal doxorubicin
- Biological · Drug
- Lead sponsor
- TILT Biotherapeutics Ltd.
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 29 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 2
- States / cities
- Rochester, Minnesota • New York, New York
- Conditions
- Colorectal Neoplasms, Gastric Neoplasms, Cholangiocarcinoma, Bile Duct Cancer, Pancreas Cancer
- Interventions
- Not listed
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 2 Years and older
- Enrollment
- 1,800 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2013
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Endometrial Cancer, Ovarian Cancer, Triple Negative Breast Cancer, GastroEsophageal Cancer, Non-small Cell Lung Cancer, Urothelial Carcinoma
- Interventions
- GEN1107
- Drug
- Lead sponsor
- Genmab
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 6
- States / cities
- Scottsdale, Arizona • Sarasota, Florida • Boston, Massachusetts + 3 more
- Conditions
- Head and Neck Squamous Cell Carcinoma
- Interventions
- HRQOL instruments, LENT SOMA instrument
- Other
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Locally Advanced Bladder Urothelial Carcinoma, Locally Advanced Renal Pelvis Urothelial Carcinoma, Locally Advanced Ureter Urothelial Carcinoma, Locally Advanced Urethral Urothelial Carcinoma, Metastatic Bladder Urothelial Carcinoma, Metastatic Renal Pelvis Urothelial Carcinoma, Metastatic Ureter Urothelial Carcinoma, Metastatic Urethral Urothelial Carcinoma, Recurrent Bladder Urothelial Carcinoma, Recurrent Renal Pelvis Urothelial Carcinoma, Recurrent Ureter Urothelial Carcinoma, Recurrent Urethral Urothelial Carcinoma, Stage III Bladder Cancer AJCC v8, Stage III Renal Pelvis Cancer AJCC v8, Stage III Ureter Cancer AJCC v8, Stage III Urethral Cancer AJCC v8, Stage IV Bladder Cancer AJCC v8, Stage IV Renal Pelvis Cancer AJCC v8, Stage IV Ureter Cancer AJCC v8, Stage IV Urethral Cancer AJCC v8, Unresectable Bladder Urothelial Carcinoma, Unresectable Renal Pelvis Urothelial Carcinoma, Unresectable Ureter Urothelial Carcinoma, Unresectable Urethral Urothelial Carcinoma
- Interventions
- Atezolizumab, Biopsy Procedure, Biospecimen Collection, Computed Tomography with Contrast, Eribulin Mesylate
- Drug · Procedure
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 72 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2027
- U.S. locations
- 21
- States / cities
- Birmingham, Alabama • Buena Park, California • Duarte, California + 15 more
- Conditions
- Advanced Clear Cell Renal Cell Carcinoma, Advanced Sarcomatoid Renal Cell Carcinoma, Metastatic Clear Cell Renal Cell Carcinoma, Metastatic Sarcomatoid Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8
- Interventions
- Biospecimen Collection, Bone Scan, Computed Tomography, Faecalibacterium prausnitzii-containing Bacterial Strain Formulation EXL01, Ipilimumab, Magnetic Resonance Imaging, Nivolumab
- Procedure · Dietary Supplement · Biological
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 2
- States / cities
- Duarte, California • Irvine, California
- Conditions
- Pancreatic Cancer, Adenocarcinoma of the Pancreas, Squamous Cell Carcinoma of Pancreas, Adenosquamous Carcinoma of the Pancreas
- Interventions
- ZIMBERELIMAB, DOMVANALIMAB, APX005M, FOLFIRI
- Drug
- Lead sponsor
- James Cleary, MD, PhD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 46 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2032
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Non Small Cell Lung Cancer
- Interventions
- Alirocumab, Cemiplimab, Chemotherapy
- Drug
- Lead sponsor
- Duke University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 63 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Extensive-stage Small-cell Lung Cancer, Liver Metastases
- Interventions
- Bevacizumab
- Drug
- Lead sponsor
- Kamya Sankar
- Other
- Eligibility
- Not listed
- Enrollment
- 39 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 3
- States / cities
- Los Angeles, California • Ann Arbor, Michigan
- Conditions
- Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma, Radiation Therapy
- Interventions
- Not listed
- Lead sponsor
- Vanderbilt University Medical Center
- Other
- Eligibility
- 28 Years and older
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Hepatocellular Carcinoma
- Interventions
- TACE transarterial chemoembolization, stereotatic body radiotherapy (SBRT)
- Radiation
- Lead sponsor
- Abramson Cancer Center at Penn Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2027
- U.S. locations
- 3
- States / cities
- Maywood, Illinois • Portland, Oregon • Philadelphia, Pennsylvania
- Conditions
- Malignant Glioma, Recurrent Glioblastoma
- Interventions
- Durvalumab, Laboratory Biomarker Analysis, Surgical Procedure, Tremelimumab
- Biological · Other · Procedure
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2020
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
- Interventions
- topotecan hydrochloride
- Drug
- Lead sponsor
- Gynecologic Oncology Group
- Network
- Eligibility
- 18 Years to 120 Years · Female only
- Enrollment
- 81 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2005
- U.S. locations
- 78
- States / cities
- Hartford, Connecticut • New Britain, Connecticut • Lewes, Delaware + 60 more
- Conditions
- Localized Prostate Carcinoma, Locally Advanced Prostate Carcinoma, Stage I Prostate Cancer American Joint Committee on Cancer (AJCC) v8, Stage II Prostate Cancer AJCC v8, Stage III Prostate Cancer AJCC v8
- Interventions
- Biospecimen Collection, Discussion, Exercise Intervention, Interview, Medical Device Usage and Evaluation, Physical Examination, Physical Performance Testing, Questionnaire Administration, Recreational Therapy
- Procedure · Other
- Lead sponsor
- University of Southern California
- Other
- Eligibility
- 55 Years to 85 Years · Male only
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 2
- States / cities
- Los Angeles, California
- Conditions
- Breast Cancer
- Interventions
- Tamoxifen, Lumpectomy, brachytherapy
- Drug · Procedure · Radiation
- Lead sponsor
- Masonic Cancer Center, University of Minnesota
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2013
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota